{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:03:16Z","timestamp":1769594596133,"version":"3.49.0"},"reference-count":26,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: Germline mutations in the BRCA1 and BRCA2 genes confer increased susceptibility to ovarian cancer. There is evidence that tumors in carriers may exhibit a distinct distribution of pathological features, but previous studies on the pathology of such tumors have been small. Our aim was to evaluate the morphologies and immunophenotypes in a large cohort of patients with familial ovarian cancer.<\/jats:p>\n               <jats:p>Experimental Design: We performed a systematic review of ovarian tumors from 178 BRCA1 mutation carriers, 29 BRCA2 mutation carriers, and 235 controls with a similar age distribution. Tumors were evaluated by four pathologists blinded to mutation status. Both morphological features and immunochemical staining for p53 and HER2 were evaluated.<\/jats:p>\n               <jats:p>Results: Tumors in BRCA1 mutation carriers were more likely than tumors in age-matched controls to be invasive serous adenocarcinomas (odds ratio, 1.84; 95% confidence interval, 1.21\u20132.79) and unlikely to be borderline or mucinous tumors. Tumors in BRCA1 carriers were of higher grade (P &amp;lt; 0.0001), had a higher percentage solid component (P = 0.001), and were more likely to stain strongly for p53 (P = 0.018). The distribution of pathological features in BRCA2 carriers was similar to that in BRCA1 carriers.<\/jats:p>\n               <jats:p>Conclusions: Use of pathological features can substantially improve the targeting of predictive genetic testing. Results also suggest that BRCA1 and BRCA2 tumors are relatively aggressive and may be expected to have poor prognosis, although this may be treatment dependent.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-1029-3","type":"journal-article","created":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T23:53:56Z","timestamp":1127346836000},"page":"2473-2481","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":205,"title":["Pathology of Ovarian Cancers in <b>\n                     <i>BRCA1<\/i>\n                  <\/b> and <b>\n                     <i>BRCA2<\/i>\n                  <\/b> Carriers"],"prefix":"10.1158","volume":"10","author":[{"given":"Sunil R.","family":"Lakhani","sequence":"first","affiliation":[{"name":"1The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"},{"name":"2The Royal Marsden Hospital, London, United Kingdom;"}]},{"given":"Sanjiv","family":"Manek","sequence":"additional","affiliation":[{"name":"3Department of Cellular Pathology, John Radcliffe Hospital, Oxford, United Kingdom;"}]},{"given":"Frederique","family":"Penault-Llorca","sequence":"additional","affiliation":[{"name":"4Centre Jean Perrin, Clermont-Ferrand, France;"}]},{"given":"Adrienne","family":"Flanagan","sequence":"additional","affiliation":[{"name":"5Department of Pathology, Royal Free & University College, London, United Kingdom;"}]},{"given":"Laurent","family":"Arnout","sequence":"additional","affiliation":[{"name":"6Service d\u2019Anatomie Pathologique, Centre G-F Leclerc, Dijon, France;"}]},{"given":"Samantha","family":"Merrett","sequence":"additional","affiliation":[{"name":"1The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Lesley","family":"McGuffog","sequence":"additional","affiliation":[{"name":"7Cancer Research U.K. Genetic Epidemiology Unit, Cambridge, United Kingdom;"}]},{"given":"Dawn","family":"Steele","sequence":"additional","affiliation":[{"name":"1The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Peter","family":"Devilee","sequence":"additional","affiliation":[{"name":"16Department of Genetics and Pathology, Leiden University, Leiden, the Netherlands;"}]},{"given":"Jan G. M.","family":"Klijn","sequence":"additional","affiliation":[{"name":"17Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands;"}]},{"given":"Hanne","family":"Meijers-Heijboer","sequence":"additional","affiliation":[{"name":"17Department of Clinical Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands;"}]},{"given":"Paolo","family":"Radice","sequence":"additional","affiliation":[{"name":"8Department of Experimental Oncology Istituto Nazionale Tumori, Milan, Italy;"}]},{"given":"Silvana","family":"Pilotti","sequence":"additional","affiliation":[{"name":"9Department of Pathology, Istituto Nazionale Tumori, Milan, Italy;"}]},{"given":"Heli","family":"Nevanlinna","sequence":"additional","affiliation":[{"name":"25Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland;"}]},{"given":"Ralf","family":"Butzow","sequence":"additional","affiliation":[{"name":"25Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland;"},{"name":"26Department of Pathology, University of Helsinki, Helsinki, Finland;"}]},{"given":"Hagay","family":"Sobol","sequence":"additional","affiliation":[{"name":"18Department of Genetic Oncology and Cancer Control, Paoli-Calmettes Institute, Marseille, France;"}]},{"given":"Jocylyne","family":"Jacquemier","sequence":"additional","affiliation":[{"name":"18Department of Genetic Oncology and Cancer Control, Paoli-Calmettes Institute, Marseille, France;"}]},{"given":"Dominique Stoppa","family":"Lyonet","sequence":"additional","affiliation":[{"name":"23Unite de Genetique Oncologique, Institut Curie, Paris, France;"}]},{"given":"Susan L.","family":"Neuhausen","sequence":"additional","affiliation":[{"name":"24Division Epidemiology, Department of Medicine, University of California Irvine, Irvine California;"}]},{"given":"Barbara","family":"Weber","sequence":"additional","affiliation":[{"name":"22Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania;"}]},{"given":"Teresa","family":"Wagner","sequence":"additional","affiliation":[{"name":"10Department of Obstetrics and Gynaecology, General Hospital, University of Vienna, Vienna, Austria;"}]},{"given":"Robert","family":"Winqvist","sequence":"additional","affiliation":[{"name":"11Department of Clinical Genetics, Oulu University Hospital\/University of Oulu, Oulu, Finland;"}]},{"given":"Yves-Jean","family":"Bignon","sequence":"additional","affiliation":[{"name":"4Centre Jean Perrin, Clermont-Ferrand, France;"}]},{"given":"Franco","family":"Monti","sequence":"additional","affiliation":[{"name":"27Laboratorio di Biologia Oncologica, Ospedale Infermi, Rimini, Italy"}]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"12Institute of Pathology and Molecular Immunology, University of Porto, R. Robert Frias, Porto, Portugal;"}]},{"given":"Gilbert","family":"Lenoir","sequence":"additional","affiliation":[{"name":"13Laboratoire de Genetique, Lyon, France;"}]},{"given":"Susanne","family":"Seitz","sequence":"additional","affiliation":[{"name":"14Mac-Delbruck-Centrum, Berlin, Germany;"}]},{"given":"Ute","family":"Hamman","sequence":"additional","affiliation":[{"name":"15Deutsches Krebsforschungszentrum, Divisions of Epidemiology and Molecular Genome Analysis, Heidelberg, Germany;"}]},{"given":"Paul","family":"Pharoah","sequence":"additional","affiliation":[{"name":"21CRUK Human Cancer Genetics Research Group, Cambridge, United Kingdom;"}]},{"given":"Geoff","family":"Lane","sequence":"additional","affiliation":[{"name":"20Department of Gynaecological Oncology, St. James University Hospital, Leeds, United Kingdom;"}]},{"given":"Bruce","family":"Ponder","sequence":"additional","affiliation":[{"name":"21CRUK Human Cancer Genetics Research Group, Cambridge, United Kingdom;"}]},{"given":"D. Timothy","family":"Bishop","sequence":"additional","affiliation":[{"name":"19Cancer Research UK (CRUK) Genetic Epidemiology Laboratory and"}]},{"given":"Douglas F.","family":"Easton","sequence":"additional","affiliation":[{"name":"7Cancer Research U.K. Genetic Epidemiology Unit, Cambridge, United Kingdom;"}]}],"member":"1086","published-online":{"date-parts":[[2004,4,8]]},"reference":[{"key":"2022061021292355400_B1","doi-asserted-by":"crossref","unstructured":"Antoniou A, Pharoah PDP, Narod S, et al Average risks of breast and ovarian cancer associated with mutations in BRCA1 or BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 72:\u20081117-30, \u20082003.","DOI":"10.1086\/375033"},{"key":"2022061021292355400_B2","doi-asserted-by":"crossref","unstructured":"Stratton JF, Gayther SA, Russell P, et al Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med, 336:\u20081125-30, \u20081997.","DOI":"10.1056\/NEJM199704173361602"},{"key":"2022061021292355400_B3","doi-asserted-by":"crossref","unstructured":"Risch HA, McLaughlin JR, Cole DE, et al Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet, 68:\u2008700-10, \u20082001.","DOI":"10.1086\/318787"},{"key":"2022061021292355400_B4","doi-asserted-by":"crossref","unstructured":"Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet, 65:\u20081021-9, \u20081999.","DOI":"10.1086\/302583"},{"key":"2022061021292355400_B5","doi-asserted-by":"crossref","unstructured":"Rubin SC, Benjamin I, Behbakht K, et al Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med, 335:\u20081413-6, \u20081996.","DOI":"10.1056\/NEJM199611073351901"},{"key":"2022061021292355400_B6","unstructured":"Berchuck A, Heron KA, Carney ME, et al Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res, 4:\u20082433-7, \u20081998."},{"key":"2022061021292355400_B7","doi-asserted-by":"crossref","unstructured":"Shaw PA, McLaughlin JR, Zweemer RP, et al Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol, 21:\u2008407-11, \u20082002.","DOI":"10.1097\/00004347-200210000-00011"},{"key":"2022061021292355400_B8","unstructured":"Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res, 59:\u2008868-71, \u20081999."},{"key":"2022061021292355400_B9","doi-asserted-by":"crossref","unstructured":"Lakhani SR, Jacquemier J, Sloane JP, et al Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (Bethesda), 90:\u20081138-45, \u20081998.","DOI":"10.1093\/jnci\/91.1.90a"},{"key":"2022061021292355400_B10","doi-asserted-by":"crossref","unstructured":"Lakhani S, Easton D, Stratton MR. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet, 349:\u20081505-10, \u20081997.","DOI":"10.1016\/S0140-6736(96)10109-4"},{"key":"2022061021292355400_B11","doi-asserted-by":"crossref","unstructured":"Lakhani SR, Van De Vijver MJ, Jacquemier J, et al The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol, 20:\u20082310-8, \u20082002.","DOI":"10.1200\/JCO.2002.09.023"},{"key":"2022061021292355400_B12","unstructured":"Huber PJ. The behaviour of maximum likelihood estimates under nonstandard conditions. Proc Berkeley Symp Math Stat Probab, 1:\u2008221-33, \u20081967."},{"key":"2022061021292355400_B13","doi-asserted-by":"crossref","unstructured":"Sakamoto A, Sasaki H, Furusato M, et al Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol, 54:\u200854-8, \u20081994.","DOI":"10.1006\/gyno.1994.1165"},{"key":"2022061021292355400_B14","unstructured":"Cramer SF, Roth LM, Ulbright TM, et al Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med, 111:\u2008819-29, \u20081987."},{"key":"2022061021292355400_B15","doi-asserted-by":"crossref","unstructured":"Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. Apmis, 99:\u2008353-8, \u20081991.","DOI":"10.1111\/j.1699-0463.1991.tb05161.x"},{"key":"2022061021292355400_B16","doi-asserted-by":"crossref","unstructured":"Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer (Phila), 82:\u2008893-901, \u20081998.","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<893::AID-CNCR14>3.0.CO;2-W"},{"key":"2022061021292355400_B17","doi-asserted-by":"crossref","unstructured":"Zweemer RP, Shaw PA, Verheijen RM, et al Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol, 52:\u2008372-5, \u20081999.","DOI":"10.1136\/jcp.52.5.372"},{"key":"2022061021292355400_B18","doi-asserted-by":"crossref","unstructured":"Werness BA, Ramus SJ, Whittemore AS, et al Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol, 31:\u20081420-4, \u20082000.","DOI":"10.1053\/hupa.2000.20379"},{"key":"2022061021292355400_B19","doi-asserted-by":"crossref","unstructured":"Werness BA, Ramus SJ, Whittemore AS, et al Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation. Int J Gynecol Pathol, 19:\u2008390-4, \u20082000.","DOI":"10.1097\/00004347-200010000-00017"},{"key":"2022061021292355400_B20","doi-asserted-by":"crossref","unstructured":"Gotlieb WH, Friedman E, Bar-Sade RB, et al Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst (Bethesda), 90:\u2008995-1000, \u20081998.","DOI":"10.1093\/jnci\/90.13.995"},{"key":"2022061021292355400_B21","doi-asserted-by":"crossref","unstructured":"Boyd J, Sonoda Y, Federici MG, et al Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA, 283:\u20082260-5, \u20082000.","DOI":"10.1001\/jama.283.17.2260"},{"key":"2022061021292355400_B22","doi-asserted-by":"crossref","unstructured":"Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol, 16:\u2008397-404, \u20081998.","DOI":"10.1200\/JCO.1998.16.2.397"},{"key":"2022061021292355400_B23","doi-asserted-by":"crossref","unstructured":"Ramus SJ, Bobrow LG, Pharoah PD, et al Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer, 25:\u200891-6, \u20081999.","DOI":"10.1002\/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5"},{"key":"2022061021292355400_B24","doi-asserted-by":"crossref","unstructured":"Zweemer RP, Verheijen RH, Gille JJ, van Diest PJ, Pals G, Menko FH. Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol, 178:\u200885-90, \u20081998.","DOI":"10.1016\/S0002-9378(98)70632-5"},{"key":"2022061021292355400_B25","unstructured":"Aida H, Takakuwa K, Nagata H, et al Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin Cancer Res, 4:\u2008235-40, \u20081998."},{"key":"2022061021292355400_B26","doi-asserted-by":"crossref","unstructured":"Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med, 8:\u2008571-6, \u20082002.","DOI":"10.1016\/S1471-4914(02)02434-6"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/10\/7\/2473\/1956885\/zdf00704002473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/10\/7\/2473\/1956885\/zdf00704002473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T02:29:16Z","timestamp":1654914556000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/10\/7\/2473\/35360\/Pathology-of-Ovarian-Cancers-in-BRCA1-and-BRCA2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2004,4,8]]},"published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-1029-3","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}